FMS: Fresenius Medical Care AG & Co. KGAA Twitter

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, March 14, 8:04 AM Fresenius Medical Care (FMS) receives a warning letter from the FDA saying that the design validation process for specific dialysis machines made in Utah is incomplete. However, the FDA doesn't require a product recall, and Fresenius doesn't expect the letter to affect its earnings guidance this year. (PR) Comment! [Healthcare]
Tuesday, February 26, 10:13 AM Fresenius Medical Care (FMS) declares annual dividend of €0.75/share, 9% increase from prior dividend of €0.69, subject to approval by shareholders. (PR) Comment! [Dividends]
Tuesday, February 26, 9:02 AM Fresenius Medical Care (FMS): Q4 net profit -17% to $257M; EBIT -4.7% to $559.1M; revenues +13% to $3.71B, North American sales +19% to $2.43B, revenue per treatment in U.S. clinics +4.8% to $368; international revenue +4% to $1.27B. Forecasts 2013 net profit of $1.1-1.2B, sales of above $14.6B, in line. Shares +2.8% in Frankfurt. (PR) Comment! [Healthcare, Earnings]
Monday, February 25, 7:28 AM Affymax (AFFY) prints at $3.41 premarket, -78.8%, following yesterday's report of the Omontys recall. AFFY has no other late-stage drugs in its pipeline. Piper expects shares to trade to cash value (~$2) "as investors take into account the lack of visibility." In play: AMGN, whose Epogen dominates the antianemia market (+2.4%), NKTR (which earns royalties on Omontys sales), and FMS, which pulled a trial two weeks ago (-1.3%). Comment! [Healthcare, On the Move]
Thursday, February 14, 9:58 AM Affymax (AFFY) collapses 28% after saying that Fresenius (FMS) is pausing the further expansion of a trial with Affymax's Omontys treatment for anemia in patients with kidney disease after injecting it in over 18,000 people. Fresenius will now study the results of the test for efficacy and safety. Fresenius said one in 1000 patients suffered allergic reactions, a small number of which were serious, although most were mild. Comment! [Healthcare, On the Move]
Monday, September 3, 2012, 4:22 AM Fresenius (FMS) drops a €3.1B bid for private-clinic operator Rhoen-Klinikum. Fresenius had planned to make a second offer at an unchanged price of €22.50/share, but the German health-care company's supervisory board wasn't overly keen on the deal, while a rival hospital operator filed an application to raise its stake in Rhoen-Klinikum to 10% in order to torpedo Fresenius. (PR) Comment! [Healthcare, M&A]
Thursday, July 12, 2012, 11:54 AM Affymax (AFFY +15.65%) after announcing that its partner, Takeda Pharmaceuticals, has signed an agreement to supply their anemia treatment Omontys to U.S. dialysis centers run by Germany's Fresenius Medical Care. Fresenius (FMS -2.1%) intends to initially use the drug in 100 centers before expanding the program. (PR) Comment! [Healthcare, On the Move]
Thursday, December 1, 2011, 12:00 PM Fresenius Medical (FMS +1.3%) gets a boost from a valuation upgrade by Morgan Stanley to Overweight from Equal Weight. Comment! [Healthcare, On the Move]
Tuesday, August 30, 2011, 9:00 AM Premarket gainers: LLNW +10%. AEZS +8%. PANL +6%. TGB +4%. DG +3%.
Losers: NBG -9%. CEDC -7%. LVLT -4%. ASBC -4%. FRO -3%. DB -3%. FMS -3%. GSK -3%. Comment! [On the Move]
Tuesday, August 2, 2011, 3:31 AM Fresenius Medical Care (FMS), the world's largest dialysis company, agrees to buy Liberty Dialysis Holdings for $1.7B including assumed debt, and American Access Care Holdings for $385M. The deals come as a new Medicare payment scheme pressures dialysis clinics to increase efficiency. (PR) Comment! [M&A, Healthcare]

FMS Fresenius Medical Care AG & Co. KGAA

FMS

Fresenius Medical Care AG & Co. KGAA